178 related articles for article (PubMed ID: 11228177)
1. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
Frazão JM; Elangovan L; Maung HM; Chesney RW; Acchiardo SR; Bower JD; Kelley BJ; Rodriguez HJ; Norris KC; Robertson JA; Levine BS; Goodman WG; Gentile D; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
[TBL] [Abstract][Full Text] [Related]
4. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
5. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
6. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
7. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
8. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
9. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
[TBL] [Abstract][Full Text] [Related]
10. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.
Fischer ER; Harris DC
Clin Nephrol; 1993 Oct; 40(4):216-20. PubMed ID: 8261678
[TBL] [Abstract][Full Text] [Related]
12. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.
Mitsopoulos E; Zanos S; Ginikopoulou E; Kyriklidou P; Meimaridou D; Sakellariou G
Am J Kidney Dis; 2006 Jul; 48(1):114-21. PubMed ID: 16797393
[TBL] [Abstract][Full Text] [Related]
13. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
17. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
[TBL] [Abstract][Full Text] [Related]
19. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
20. Doxercalciferol treatment of secondary hyperparathyroidism.
Dennis VC; Albertson GL
Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
